Every 8-K that Soligenix, Inc. (SNGX) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 8-K covers material events a company has to report between its quarterly reports, so if you follow SNGX and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full SNGX filings page.
Soligenix, Inc. (SNGX) reported results of its September 17, 2026 annual meeting, where stockholders approved an amendment to its Certificate of Incorporation increasing authorized common stock from 75,000,000 to 125,000,000, effective upon filing with the Delaware Secretary of State on September 17, 2026.
Stockholders also approved a charter amendment authorizing the board, for up to one year, to implement a reverse stock split of issued and outstanding common stock at a ratio between 1-for-2 and 1-for-20, with the exact ratio to be set and publicly announced by the board. All five director nominees were elected, say-on-pay and an annual frequency for future say-on-pay votes were approved, the appointment of Cherry Bekaert LLP as auditor for 2026 was ratified, and an adjournment proposal was approved.
Separately, Soligenix disclosed that on June 26, 2026 it filed a prospectus supplement increasing by $2,500,000 the maximum aggregate amount of common stock issuable under its At Market Issuance Sales Agreement with Rodman & Renshaw LLC. The company has previously sold approximately $6,234,000 of common stock under prior supplements covering up to $6,406,000.
Soligenix, Inc. increased by $2,500,000 the maximum aggregate amount of its common stock that may be issued under its at-the-market sales agreement with Rodman & Renshaw LLC, through a new prospectus supplement. The company previously sold about $6,234,000 of common stock under earlier supplements that covered up to $6,406,000 of shares. The 8-K also files the related legal opinion from Duane Morris LLP as an exhibit.
Soligenix, Inc. is ending development of its HyBryte™ therapy and has received a Nasdaq warning about its share price. The board decided on June 11, 2026 to terminate the HyBryte™ program after an interim analysis of the Phase 3 FLASH2 trial recommended stopping for futility. The company will wind down the study and related work and expects about $70,000 in close‑out charges. Soligenix also received notice on June 10, 2026 that its stock has traded below Nasdaq’s $1.00 minimum bid price for 30 consecutive business days, triggering a 180‑day grace period, until December 7, 2026, to regain compliance. If needed and other listing conditions are met, Soligenix may seek an additional 180‑day period, potentially via a reverse stock split. In connection with ending HyBryte™, Consulting Chief Medical Officer Dr. Richard Straube’s role will wind down, with responsibilities shifting to Medical Director Dr. Christopher Pullion. The company plans to evaluate strategic options, including mergers and acquisitions, and focus on other pipeline assets such as dusquetide (SGX945) for Behçet’s Disease.
Soligenix, Inc. filed a prospectus supplement to increase the maximum aggregate offering amount of its common stock under an existing At Market Issuance Sales Agreement with Rodman & Renshaw LLC by an additional $2,956,000.
The company previously sold approximately $3,445,000 of common stock under this agreement pursuant to an earlier prospectus supplement. A legal opinion from Duane Morris LLP covering the additional $2,956,000 of common stock is included as an exhibit, along with the related consent and an Inline XBRL cover page data file.
Soligenix, Inc. announced that an interim efficacy analysis by the Data Monitoring Committee for its pivotal Phase 3 FLASH2 trial of HyBryte™ in cutaneous T‑cell lymphoma recommended the study halt for futility. The company expressed disappointment and plans to analyze the data to understand why efficacy did not meet expectations and whether specific patient subsets might still benefit.
With approximately $5.9 million of cash, Soligenix says it will evaluate strategic options, including potential mergers or acquisitions and advancing dusquetide for Behçet’s Disease. The company cautions that, following discontinuation of FLASH2, its ability to continue as a going concern depends on successfully developing remaining pipeline assets and securing sufficient capital; failure to do so could require significant downsizing, asset sales, or liquidation.
Soligenix, Inc. filed a report highlighting a shareholder update letter from its CEO on pipeline progress, milestones, financing and cash runway. The company states it has sufficient capital to meet its goals through 2026 and continues to pursue strategic options, including partnerships and potential M&A.
Soligenix expects peak annual net sales of HyBryte™ in the U.S. to exceed $90 million, within a worldwide CTCL market estimated at more than $250 million annually. The worldwide psoriasis opportunity for SGX302 is estimated to exceed $1 billion annually, and SGX945 in Behçet's Disease about $200 million, supporting a total potential of roughly $2 billion in global annual sales.
The company reported approximately $10.5 million in cash as of the quarter ended September 30, 2025, plus about $500 thousand from New Jersey’s NOL sales program, and remains focused on completing the confirmatory Phase 3 HyBryte™ FLASH2 trial and advancing ex-U.S. partnership discussions.
Soligenix, Inc. has entered into an at-the-market equity sales agreement with Rodman & Renshaw, LLC, allowing the company to sell shares of its common stock from time to time with an aggregate offering price of up to $3,450,000. Sales, if any, will be made through Rodman as sales agent on The Nasdaq Capital Market or other U.S. trading markets, at market-related or negotiated prices, as defined in Rule 415 under the Securities Act.
The company will control key parameters for each sales period, such as the number of shares sold, time window, daily volume limits, and any minimum price. Soligenix is not obligated to sell any shares, may suspend solicitations, and either party may terminate the agreement under specified conditions, with the program ending no later than December 15, 2026 unless ended earlier. Rodman will receive a commission of up to 3.0% of gross proceeds, and shares will be issued under Soligenix’s effective Form S-3 shelf registration statement and a related prospectus supplement.
Soligenix, Inc. reports that it has regained compliance with Nasdaq’s minimum stockholders’ equity listing standard. Nasdaq requires at least $2,500,000 of stockholders’ equity for companies on The Nasdaq Capital Market. In its Quarterly Report for the quarter ended September 30, 2025, Soligenix reported stockholders’ equity of $7,597,976, which exceeded this requirement. On November 18, 2025, Nasdaq sent a letter confirming the company is again in compliance and that the listing matter is closed.
Soligenix, Inc. entered into a securities purchase agreement for a public equity offering consisting of common stock, pre-funded warrants and common warrants. The company agreed to sell 4,064,080 shares of common stock, pre-funded warrants to purchase 1,491,480 shares, and common warrants to purchase 5,555,560 shares, sold in units. Each common stock unit with a common warrant was priced at $1.35, and each pre-funded warrant unit with a common warrant at $1.349, with the common warrants exercisable at $1.35 per share for five years.
The offering closed with aggregate gross proceeds of approximately $7.5 million before fees and expenses, which the company states extends its cash runway through the end of 2026. Soligenix plans to use the net proceeds for research, development and commercialization activities and general corporate and working capital purposes. The company agreed to a 60-day lock-up on new issuances and a one-year restriction on variable rate transactions, and also reduced the exercise price of certain existing warrants to $1.35 and aligned their expiration with the new warrants.
Soligenix, Inc. reported that the U.S. Food and Drug Administration’s Office of Orphan Products Development has granted orphan drug designation to dusquetide, the active ingredient in its drug candidate SGX945, for the treatment of Behçet’s Disease. This decision follows review of recent Phase 2a clinical results that showed biological efficacy and safety in patients with Behçet’s Disease.
The company highlighted that this regulatory milestone is based on early-stage clinical data and cautioned that forward-looking statements are subject to significant risks and uncertainties described in its periodic SEC reports.
Soligenix, Inc. reported that it received a notice from Nasdaq on August 15, 2025 stating the company no longer meets the minimum stockholders’ equity requirement of $2,500,000 for continued listing on The Nasdaq Capital Market. In its Form 10-Q for the quarter ended June 30, 2025, Soligenix reported stockholders’ equity of $1,828,951, below this threshold, although this figure does not include gross proceeds of approximately $1,439,300 from sales under its At-The-Market facility on July 1, 2025.
The company also does not satisfy Nasdaq’s alternative continued listing standards based on market value or net income. The notice does not immediately affect trading, and the stock continues to trade on Nasdaq under the symbol SNGX. Soligenix has 45 calendar days, until September 29, 2025, to submit a plan to regain compliance, and Nasdaq may grant up to 180 days from the notice date to evidence compliance. If the plan is not accepted or compliance is not regained, the company’s common stock could become subject to delisting, with the possibility of an appeal to a Nasdaq Hearings Panel.